In recent years, the drug treatment for NSCLC has developed from chemotherapeutic drugs to targeted drugs, wherein epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are targeted drugs that target EGFR for anticancer treatment. This evidence concerns the gene EGFR and non-small cell lung carcinoma.